HELSINKI – The Covid-19 pandemic has clearly demonstrated the importance of efficient mass screening and rapid diagnosis in determining the status of the spread as well as in setting targeted response strategies for containing the outbreak.
During the pandemic various diagnostics methods have been utilized, and rapid tests have gained increasing interest.
Rapid antigen tests are ideal for decentralized testing and can deliver fast and actionable results, ensuring timely identification of people infected with the virus at the community level. They have become key for point-of-care Covid-19 testing due to faster test results (15 minutes), without the need for laboratory infrastructure or expensive equipment.
Ahlstrom-Munksjö has been developing components for rapid test kits for decades and since the beginning of the pandemic, has been supporting diagnostics companies in their efforts to develop efficient Covid-19 screening devices with its ReliaFlow range of products.
Specifically designed for use in flow-through and lateral flow assays, the ReliaFlow portfolio includes:
- Sample pads for blood, saliva and other liquid samples to meet the most demanding requirements.
- A conjugate release pads range from which manufacturers can choose the best solution for different applications, combining high performances and improved processability during manufacture of the kits.
- Absorbent pads which ensure proper flow
“The rapid spread of Covid-19 has inevitably led to an increase in the need for healthcare goods including diagnostics and screening tools,” said Laia Guarro, VP of Liquid Technologies at Ahlstrom-Munksjö. “We are fully committed to supporting our in providing faster, more accessible and reliable tests.”